JP2013528661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528661A5 JP2013528661A5 JP2013515572A JP2013515572A JP2013528661A5 JP 2013528661 A5 JP2013528661 A5 JP 2013528661A5 JP 2013515572 A JP2013515572 A JP 2013515572A JP 2013515572 A JP2013515572 A JP 2013515572A JP 2013528661 A5 JP2013528661 A5 JP 2013528661A5
- Authority
- JP
- Japan
- Prior art keywords
- bitter
- individual
- taste receptor
- bitter taste
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims 36
- 235000019658 bitter taste Nutrition 0.000 claims 35
- 108091005708 gustatory receptors Proteins 0.000 claims 32
- 239000000126 substance Substances 0.000 claims 23
- 108020003175 receptors Proteins 0.000 claims 17
- 102000005962 receptors Human genes 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 230000009885 systemic effect Effects 0.000 claims 14
- 238000010521 absorption reaction Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 12
- 239000005556 hormone Substances 0.000 claims 12
- 229940088597 hormone Drugs 0.000 claims 12
- 230000002503 metabolic effect Effects 0.000 claims 12
- 230000000295 complement effect Effects 0.000 claims 10
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 10
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 5
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims 5
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims 5
- 229920002079 Ellagic acid Polymers 0.000 claims 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 5
- 230000004913 activation Effects 0.000 claims 5
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 claims 5
- 235000012754 curcumin Nutrition 0.000 claims 5
- 229940109262 curcumin Drugs 0.000 claims 5
- 239000004148 curcumin Substances 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 235000004132 ellagic acid Nutrition 0.000 claims 5
- 229960002852 ellagic acid Drugs 0.000 claims 5
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 5
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 claims 5
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 claims 5
- 208000019423 liver disease Diseases 0.000 claims 5
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- YYNJYMYRHBOARL-UHFFFAOYSA-N 7-methoxyquinoxalin-5-amine Chemical compound N1=CC=NC2=CC(OC)=CC(N)=C21 YYNJYMYRHBOARL-UHFFFAOYSA-N 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- NVLPQIPTCCLBEU-UHFFFAOYSA-N allyl methyl sulphide Natural products CSCC=C NVLPQIPTCCLBEU-UHFFFAOYSA-N 0.000 claims 4
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 claims 4
- 229960001610 denatonium benzoate Drugs 0.000 claims 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 4
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 claims 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 230000008512 biological response Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- -1 rottrelin Natural products 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39794010P | 2010-06-17 | 2010-06-17 | |
| US61/397,940 | 2010-06-17 | ||
| PCT/US2011/040994 WO2011160093A2 (en) | 2010-06-17 | 2011-06-17 | Methods and systems for modulating hormones and related methods, agents and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013528661A JP2013528661A (ja) | 2013-07-11 |
| JP2013528661A5 true JP2013528661A5 (https=) | 2014-08-28 |
Family
ID=45348917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013515572A Pending JP2013528661A (ja) | 2010-06-17 | 2011-06-17 | ホルモン調節方法およびシステムならびに関連する方法、作用剤および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8796233B2 (https=) |
| EP (1) | EP2582367A4 (https=) |
| JP (1) | JP2013528661A (https=) |
| KR (2) | KR20160074015A (https=) |
| CN (1) | CN103068380A (https=) |
| WO (1) | WO2011160093A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2582367A4 (en) * | 2010-06-17 | 2013-11-27 | California Inst Of Techn | METHOD AND SYSTEM FOR MODULATING HORMONES AND RELATED METHODS, ACTIVE SUBSTANCES AND COMPOSITIONS |
| MX2013004364A (es) * | 2010-10-19 | 2013-07-02 | Elcelyx Therapeutics Inc | Terapias a base de ligando del receptor quimiosensorial. |
| EP2661266B1 (en) | 2011-01-07 | 2020-09-16 | Anji Pharma (US) LLC | Chemosensory receptor ligand-based therapies |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| KR20190120430A (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| EP2800562A2 (en) | 2012-01-06 | 2014-11-12 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| JP2014148474A (ja) * | 2013-01-31 | 2014-08-21 | Chube Univ | Ｇｌｐ−１分泌促進剤 |
| JP2015083548A (ja) * | 2013-10-25 | 2015-04-30 | 花王株式会社 | 血中ｇｌｐ−１濃度上昇促進剤 |
| US12551526B2 (en) * | 2015-04-22 | 2026-02-17 | Cedars-Sinai Medical Center | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes |
| CN105699545A (zh) * | 2016-04-25 | 2016-06-22 | 广西壮族自治区梧州食品药品检验所 | 一种测定银马解毒颗粒中甘草酸铵含量的方法 |
| US10835505B2 (en) | 2018-06-11 | 2020-11-17 | Aardvark Therapeutics, Inc. | Oral pharmaceutical formulation for weight loss, diabetes and related disorders |
| US12201593B2 (en) | 2018-07-02 | 2025-01-21 | Aardvark Therapeutics Inc. | Oral pharmaceutical formulations of bitter compounds for asthma |
| WO2020014494A1 (en) | 2018-07-11 | 2020-01-16 | Aardvark Therapeutics Inc. | Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension |
| KR102140493B1 (ko) * | 2019-05-30 | 2020-08-03 | 충북대학교 산학협력단 | 데나토늄을 유효성분으로 포함하는 골 질환의 예방 또는 치료용 조성물 |
| EP4034082A4 (en) | 2019-09-25 | 2023-07-05 | Aardvark Therapeutics Inc. | Oral pharmaceutical immediate release composition and method of treatment for weight loss |
| EP4081201A4 (en) * | 2019-12-24 | 2024-01-10 | Aardvark Therapeutics Inc. | Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders |
| ES2894177A1 (es) * | 2020-08-07 | 2022-02-11 | Univ Rovira I Virgili | Composición y método para modular la ingesta de alimentos |
| JP2022099458A (ja) * | 2020-12-23 | 2022-07-05 | 株式会社東洋新薬 | グルカゴン様ペプチド－１分泌促進用組成物 |
| CA3204811A1 (en) * | 2021-02-01 | 2022-08-04 | Zhenhuan ZHENG | Denatonium salt for use in preventing, preventing progression and treating fatty liver diseases |
| CA3215858A1 (en) * | 2021-04-27 | 2022-11-03 | Zhenhuan ZHENG | Combination of bitter receptor agonist and gut-signaling compound |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3039933A (en) * | 1957-10-07 | 1962-06-19 | Premo Pharmaceutical Lab Inc | Ethyl cellulose-polyethylene glycol tablet matrix |
| US6500459B1 (en) * | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| EP1214343A2 (en) * | 1999-09-10 | 2002-06-19 | The Regents Of The University Of California | T2r taste receptor family |
| DE10031955A1 (de) * | 2000-06-30 | 2002-01-17 | Deutsches Krebsforsch | Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel |
| US20020192310A1 (en) | 2001-02-02 | 2002-12-19 | Bland Jeffrey S. | Medical composition for managing hormone balance |
| US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
| US8030008B2 (en) | 2001-04-05 | 2011-10-04 | Senomyx, Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
| CN1610830A (zh) | 2001-07-10 | 2005-04-27 | 塞诺米克斯公司 | 特异性t2r味觉受体在鉴定阻断苦味觉的化合物中的应用 |
| US20060019346A1 (en) * | 2002-07-29 | 2006-01-26 | Senomyx, Inc. | Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands |
| KR100523336B1 (ko) | 2003-03-12 | 2005-10-24 | (주)바이오버드 | 수불용성 쿠르쿠민의 수용화 방법 |
| US20050019435A1 (en) * | 2003-07-21 | 2005-01-27 | Jeffrey Young | Method of treating non-insulin dependent diabetes mellitus and related complications |
| CN1676132A (zh) * | 2004-03-30 | 2005-10-05 | 贵州圣济堂制药有限公司 | 丙硫氧嘧啶制剂及其制备方法 |
| US7858080B2 (en) * | 2005-05-20 | 2010-12-28 | Agency For Science, Technology And Research | Aldehyde conjugated flavonoid preparations |
| US20090022806A1 (en) * | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
| US7390514B2 (en) | 2005-11-28 | 2008-06-24 | Sahajanand Biotech Pvt. Ltd. | Herbal composition for treatment and maintenance of hormone dependent conditions, osteoporosis, circulatory conditions, and for use as an immunostimulant |
| EP2749552B1 (en) * | 2007-04-17 | 2015-11-18 | Codman & Shurtleff, Inc. | Curcumin-resveratrol hybrids |
| US9221877B2 (en) * | 2008-09-19 | 2015-12-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Curcumin conjugates for treating and preventing cancers |
| BRPI0919648A2 (pt) * | 2008-10-29 | 2015-12-08 | Hoffmann La Roche | novos derivados de fenil amida ou piridil amida e seu uso como agonistas de gpbar1 |
| EP2924112A1 (en) * | 2009-02-02 | 2015-09-30 | Chromocell Corporation | Novel cell lines and methods |
| EP2582367A4 (en) * | 2010-06-17 | 2013-11-27 | California Inst Of Techn | METHOD AND SYSTEM FOR MODULATING HORMONES AND RELATED METHODS, ACTIVE SUBSTANCES AND COMPOSITIONS |
-
2011
- 2011-06-17 EP EP11796562.4A patent/EP2582367A4/en not_active Withdrawn
- 2011-06-17 KR KR1020167015704A patent/KR20160074015A/ko not_active Ceased
- 2011-06-17 CN CN2011800387714A patent/CN103068380A/zh active Pending
- 2011-06-17 US US13/163,638 patent/US8796233B2/en active Active
- 2011-06-17 KR KR1020137000152A patent/KR20130112019A/ko not_active Ceased
- 2011-06-17 JP JP2013515572A patent/JP2013528661A/ja active Pending
- 2011-06-17 WO PCT/US2011/040994 patent/WO2011160093A2/en not_active Ceased
-
2014
- 2014-06-30 US US14/320,159 patent/US9272051B2/en active Active
-
2016
- 2016-01-29 US US15/009,824 patent/US10330678B2/en active Active
-
2019
- 2019-06-24 US US16/450,342 patent/US20200072832A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528661A5 (https=) | ||
| Kannt et al. | Activation of thyroid hormone receptor‐β improved disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis | |
| Nauck et al. | The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions | |
| Darsalia et al. | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride | |
| Müller et al. | Expression, regulation and function of intestinal drug transporters: an update | |
| Thulesen et al. | Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice | |
| Nyholm et al. | Irregular gastrointestinal drug absorption in Parkinson's disease | |
| McCreight et al. | Metformin and the gastrointestinal tract | |
| Xing et al. | Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver | |
| Lalić-Popović et al. | Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat | |
| Brønden et al. | Single-dose metformin enhances bile acid–induced glucagon-like peptide-1 secretion in patients with type 2 diabetes | |
| Minamii et al. | Mechanisms of metformin action: in and out of the gut | |
| van de Laarschot et al. | The role of bile salts in liver regeneration | |
| Kirwan et al. | Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis | |
| Piglionica et al. | The gut–liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19 | |
| Saber et al. | Renin–angiotensin system inhibition ameliorates CCl4-induced liver fibrosis in mice through the inactivation of nuclear transcription factor kappa B | |
| Sun et al. | Metformin triggers PYY secretion in human gut mucosa | |
| Almukainzi et al. | Modelling the absorption of metformin with patients post gastric bypass surgery | |
| Kanasaki et al. | Relevance of autophagy induction by gastrointestinal hormones: focus on the incretin-based drug target and glucagon | |
| Mundaca-Uribe et al. | A microstirring oral pill for improving the glucose-lowering effect of metformin | |
| Behm et al. | Dexlansoprazole MR for the management of gastroesophageal reflux disease | |
| Jensen et al. | Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists | |
| Gahr et al. | Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma-review of the underlying molecular mechanisms and first case report | |
| Ueno et al. | Mechanism of bile acid reabsorption in the biliopancreatic limb after duodenal-jejunal bypass in rats | |
| Inoue et al. | Dipeptidyl peptidase IV inhibition potentiates amino acid-and bile acid-induced bicarbonate secretion in rat duodenum |